Tribe Capital
Tribe Capital, established in 2018 and headquartered in Menlo Park, California, is a venture capital firm that invests in seed to growth-stage technology companies. With $1.6 billion in assets under management, the firm is known for its data-driven approach, leveraging AI and data science to model venture-backed private companies and provide deep insights to accelerate sustainable growth. Tribe's team, comprising investors, engineers, and scientists, has honed these tools at major tech and finance companies. They use quantitative analysis to measure product-market fit and identify high-growth potential "N-of-1" companies, aiming to minimize loss ratio. Notable investments include Apollo.io, Carta, Docker, Kraken, Instabase, Relativity Space, and Shiprocket.
Ashvattha Therapeutics
Series B in 2025
Ashvattha Therapeutics, Inc. is a biotechnology company focused on developing pharmaceutical products that address unmet medical needs in neurology, oncology, and ophthalmology, as well as inflammatory diseases. Founded in 2015 and headquartered in Redwood City, California, with research facilities in Baltimore, Maryland, the company specializes in hydroxyl dendrimer therapeutics. These innovative therapies are designed to selectively target actively endocytosing cells, such as reactive microglia and macrophages, which play significant roles in chronic inflammation and disease progression. By improving precision targeting, Ashvattha aims to minimize off-target toxicity, systemic side effects, and immunogenicity commonly associated with other therapeutic platforms. The company currently has a pipeline of nine therapeutics under development, focusing on enhancing treatment efficacy while reducing adverse effects for patients.
Ashvattha Therapeutics
Series B in 2021
Ashvattha Therapeutics, Inc. is a biotechnology company focused on developing pharmaceutical products that address unmet medical needs in neurology, oncology, and ophthalmology, as well as inflammatory diseases. Founded in 2015 and headquartered in Redwood City, California, with research facilities in Baltimore, Maryland, the company specializes in hydroxyl dendrimer therapeutics. These innovative therapies are designed to selectively target actively endocytosing cells, such as reactive microglia and macrophages, which play significant roles in chronic inflammation and disease progression. By improving precision targeting, Ashvattha aims to minimize off-target toxicity, systemic side effects, and immunogenicity commonly associated with other therapeutic platforms. The company currently has a pipeline of nine therapeutics under development, focusing on enhancing treatment efficacy while reducing adverse effects for patients.
Ashvattha Therapeutics
Convertible Note in 2020
Ashvattha Therapeutics, Inc. is a biotechnology company focused on developing pharmaceutical products that address unmet medical needs in neurology, oncology, and ophthalmology, as well as inflammatory diseases. Founded in 2015 and headquartered in Redwood City, California, with research facilities in Baltimore, Maryland, the company specializes in hydroxyl dendrimer therapeutics. These innovative therapies are designed to selectively target actively endocytosing cells, such as reactive microglia and macrophages, which play significant roles in chronic inflammation and disease progression. By improving precision targeting, Ashvattha aims to minimize off-target toxicity, systemic side effects, and immunogenicity commonly associated with other therapeutic platforms. The company currently has a pipeline of nine therapeutics under development, focusing on enhancing treatment efficacy while reducing adverse effects for patients.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at
support@teaserclub.com. Your feedback is most welcome.